What do clinical trials teach us about the pathophysiology of human IgA nephropathy?

This review examines recent and ongoing clinical trials for IgA nephropathy (IgAN), discussing how they shed light on the disease's mechanisms and potential treatment targets. The "four-hit hypothesis" of IgAN development is discussed, along with trials evaluating treatments targeting B cells, the complement system, and non-immunomodulatory drugs that reduce kidney stress.

The authors declared various financial relationships with pharmaceutical companies involved in developing treatments for IgA nephropathy.

This review provides a comprehensive and up-to-date overview of clinical trials in IgA nephropathy, offering valuable insights into the disease's pathophysiology and treatment strategies. The declared conflicts of interest are noted and considered in the rating.